bvb 808

Ofloxacin HCl is a synthetic fluoroquinolone ( FLUOROQUINOLONES) antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.

BVB-808 is a selective Jak2 type 1 inhibitor. Janus kinases are critical components of signaling pathways that regulate hematopoiesis. Mutations of the non-receptor tyrosine kinase JAK2 are found in many BCR-ABL-negative myeloproliferative neoplasms. Preclinical results support that JAK2 inhibitors could show efficacy in treating chronic myeloproliferative neoplasms. JAK2 has also been postulated to play a role in BCR-ABL signal transduction. Therefore, inhibitors of JAK2 kinases are turning into therapeutic strategies for treatment of chronic myelogenous leukemia (CML).

BVB808 (NVP_BVB808) is a selective inhibitor of JAK2, exhibiting approximately 10 times greater selectivity for JAK2 compared to other members of the JAK family (such as JAK1, JAK3, or TYK2) in vitro. By inhibiting the activation of JAK2, BVB808 reduces the phosphorylation of STAT5, thereby blocking the cell proliferation and survival signaling pathways that depend on JAK2. This compound is utilized in cancer research.